Pharmacovigilance Services UAE & Saudi Arabia
Maintain post-market safety compliance with structured pharmacovigilance services UAE and pharmacovigilance Saudi Arabia support. Wellness Traffic helps marketing authorisation holders and pharmaceutical companies set up and maintain the systems needed for safety monitoring, adverse-event reporting, QPPV arrangements, PSMF maintenance, periodic safety reporting and ongoing authority readiness.
Approval is not the end of regulatory responsibility. A functioning pharmacovigilance system must continue to capture, assess, document and report safety information throughout the product lifecycle.
What a Functioning Pharmacovigilance System Needs
A compliant pharmacovigilance system UAE or Saudi system is not just one safety document. It combines responsible personnel, procedures, safety-data handling, reporting timelines, quality controls and traceable records.
Core PV Readiness Checks
-
QPPV & Responsibility Structure
Define the <strong>Qualified Person Responsible for Pharmacovigilance</strong>, backup arrangements, delegated activities, authority contacts and internal safety responsibilities.
-
PSMF / Safety System Documentation
Maintain the <strong>Pharmacovigilance System Master File</strong> and related controlled documents so the current safety system can be demonstrated during review, audit or inspection.
-
Adverse Event & ICSR Handling
Establish intake, assessment, follow-up, coding, medical review, submission and reconciliation procedures for <strong>Individual Case Safety Reports</strong> and other reportable safety information.
-
Periodic Reporting & Signal Oversight
Plan <strong>PSUR / PBRER</strong>, risk-management, signal review, safety communication and post-market activities according to the product and authority requirements.
Core Pharmacovigilance Services We Support
Our drug safety services UAE and Saudi support can cover the operational and documented parts of the safety system, depending on the MAH, product portfolio and current regulatory setup.
QPPV Setup & Local Arrangements
Support for QPPV UAE and Saudi QPPV readiness, role definition, backup structure, appointment documentation and authority-facing responsibilities.
PSMF Preparation & Maintenance
PSMF preparation, updates, annex control, organizational mapping, delegated activities and maintenance of a current safety-system description.
Adverse Event & ICSR Management
Processes for safety-case intake, triage, follow-up, medical review, reconciliation and ICSR reporting to the relevant authority when required.
PSUR / PBRER & Periodic Reporting
Support for Periodic Safety Update Reports, PBRER planning and periodic safety deliverables according to the applicable reporting obligations.
Risk Management & Signal Activities
Support for risk-management documentation, safety-signal review, benefit-risk follow-up and safety actions that may be required during the product lifecycle.
SOPs, Training & Inspection Readiness
Develop and maintain pharmacovigilance SOPs, training records, compliance evidence, quality controls and inspection-ready documentation.
How We Build & Maintain a Pharmacovigilance System
Our pharmacovigilance consulting UAE and Saudi workflow begins with the current MAH setup and ends with an operating safety system that can be maintained, audited and adapted as the product portfolio changes.
01.
Assess the Existing PV System
We review the MAH structure, products, responsible personnel, existing pharmacovigilance procedures, safety databases, reporting arrangements and current authority commitments.
Stage 01
- PV Gap Review
02.
Define QPPV, Governance & Responsibilities
We map QPPV and backup roles, local and global interfaces, delegated activities, escalation routes and the responsibilities of affiliates, distributors or service providers.
Stage 02
- Governance
03.
Build PSMF, SOPs & Safety Workflows
We structure the PSMF, SOPs, case-management workflows, training requirements, quality controls and other documents needed to describe and operate the system.
Stage 03
- System Build
04.
Operate Safety Reporting & Periodic Compliance
Support adverse-event handling, ICSR reporting, periodic safety reports, signal and risk activities, reconciliations and authority-facing safety obligations.
Stage 04
- Safety Operations
05.
Maintain Inspection & Lifecycle Readiness
Keep the PV system current as products, partners, QPPV details and procedures change, with records organized for pharmacovigilance audit or authority inspection.
Stage 05
- Ongoing Compliance
UAE vs Saudi Pharmacovigilance: Local Safety Systems Have Different Requirements
The core principles of Good Pharmacovigilance Practice are similar, but local QPPV, PSMF, reporting, inspection and authority expectations must be checked market by market. Wellness Traffic separates the UAE and Saudi obligations instead of treating the GCC as one identical PV system.
UAE — EDE Pharmacovigilance
The Emirates Drug Establishment (EDE) now publishes current pharmacovigilance services and a 2026 Pharmacovigilance Practice guideline. EDE’s QPPV service states that the QPPV must be a licensed doctor or pharmacist residing in the UAE and hold recognized pharmacovigilance training.
- UAE-resident QPPV arrangement aligned with EDE requirements
- Company pharmacovigilance plan and defined manufacturing / MAH responsibilities
- ICSR, special-situation, PSUR / PBRER and risk-management processes
- SOPs, training, quality system and inspection-readiness evidence
Saudi Arabia — SFDA Good Pharmacovigilance Practice
SFDA’s current Good Pharmacovigilance Practice guideline requires a functioning pharmacovigilance system and PSMF for authorized medicinal products. The guideline states that the QPPV residence, QPPV work location and PSMF location must be within Saudi Arabia.
- Saudi-based QPPV and PSMF-location requirements
- PSMF content, annexes, delegated activities and current system description
- MAH oversight remains required even when PV activities are outsourced
- Ongoing case reporting, risk management, periodic reporting and inspection readiness
Why Pharmacovigilance Systems Fall Out of Compliance
A safety system can look complete on paper but still fail during day-to-day operation. These are common pharmacovigilance compliance gaps we look for.
Pharmacovigilance Inspection & Audit Readiness
Pharmacovigilance inspection readiness means being able to show that the safety system described in your documents is the same system your team actually operates. We review both the controlled documentation and the evidence that demonstrates ongoing compliance.
System Documentation
- Current PSMF / local PV-system documentation
- QPPV, deputy / backup and delegated-activity documentation
- Controlled pharmacovigilance SOPs and work instructions
- Vendor, affiliate and distributor safety agreements where applicable
- Training plans, role descriptions and organizational records
- Product list, reporting calendar and risk-management records
Operational Compliance Evidence
- ICSR intake, follow-up, submission and reconciliation evidence
- PSUR / PBRER and periodic deliverable tracking
- Signal, risk-management and safety-action records
- Deviation, CAPA and quality-monitoring records
- Training completion and competency evidence
- Audit, inspection and previous finding follow-up where applicable
Compliance That Has to Hold Long After Product Launch
Pharmacovigilance is continuous. New adverse events, literature, partner reports, periodic safety obligations, product changes and authority questions can all change the safety workload after launch.
Our post-market pharmacovigilance services are designed to keep the safety system current rather than creating a one-time compliance file that becomes obsolete after registration.
The System Must Be Operational, Traceable & Defensible
Authorities can assess not only whether a policy exists, but whether safety information is captured, reviewed, submitted, reconciled and retained through a controlled pharmacovigilance quality system.
— Wellness Traffic Regulatory Team
Pharmacovigilance UAE & Saudi Arabia FAQs
Direct answers about pharmacovigilance UAE, Saudi pharmacovigilance, QPPV, PSMF, adverse-event reporting, PSUR / PBRER and inspection readiness.
Need to Build or Repair Your Pharmacovigilance System?
Share your product portfolio, MAH structure, current QPPV arrangement and existing safety documents. We can help identify the major PV compliance gaps and the next system priorities.
Pharmacovigilance is the system used to detect, assess, understand, report and help prevent adverse effects and other medicine-related safety problems after and during the product lifecycle.
The Marketing Authorization Holder remains responsible for the product safety system. EDE also has a current service for approving the Qualified Person Responsible for Pharmacovigilance (QPPV) for pharmaceutical establishments.
EDE currently states that the QPPV must be a licensed doctor or pharmacist residing in the UAE, hold recognized pharmacovigilance training and be appointed directly by the Marketing Authorization Holder company.
A Pharmacovigilance System Master File (PSMF) is the controlled description of the pharmacovigilance system used by the MAH. It documents the organization, responsible people, processes, systems, delegated activities, quality controls and supporting annexes.
SFDA's current Good Pharmacovigilance Practice guideline states that the QPPV's residence, the location where the QPPV performs duties and the PSMF location must be within Saudi Arabia.
An Individual Case Safety Report (ICSR) is a structured safety report concerning an individual patient or case. PV systems need procedures for intake, assessment, follow-up, medical review, submission and reconciliation of reportable cases.
PSUR and PBRER are periodic safety reports used to evaluate accumulated safety information and the benefit-risk profile of a medicinal product according to the applicable reporting schedule and authority requirements.
Yes, certain pharmacovigilance activities can be outsourced, but the MAH retains ultimate responsibility for compliance. SFDA's current GVP explicitly states that PSMF-related work can be outsourced while the MAH remains responsible.
Yes. We can help review PSMF and SOP readiness, QPPV documentation, case-management evidence, periodic reporting controls, training, vendor oversight, quality records and other pharmacovigilance inspection readiness materials.
No. Final inspection outcomes belong to the relevant authority or auditor. Our role is to improve system readiness, document current practice accurately and reduce avoidable compliance gaps.
Stay Updated on UAE & Saudi Drug Safety Requirements
Receive practical updates on UAE pharmacovigilance, Saudi GVP, QPPV, PSMF, safety reporting, PSUR / PBRER, risk management and post-market compliance.
